Staff profiles

I am a statistician with interests in methods for improving the efficiency of clinical trials through better design and analysis approaches. As well as working in methodology development I have a great interest in collaborating on real trials to apply new methods in practice.

I have been in Newcastle since July 2017. I am part of the Biostatistics Research Group.

I started an NIHR Research Professorship in Dec 2021. My programme of work focuses on improving trials for immune-mediated inflammatory diseases. 

Areas of expertise

• Biostatistics
• Clinical trials
• Novel trial design

Google scholar: Click here.

SCOPUS: Click here.

My research focuses on statistical methods for improved design and analysis of clinical trials. I am particularly interested in:

1) Adaptive designs for clinical trials;

2) Methods for incorporating biomarkers into clinical trials to stratify patients by treatment response;

3) Improved methods for analysing composite endpoints, in particular ones with continuous components.

• Kunzmann K, Grayling MJ, Lee KM, Robertson DS, Rufibach K, Wason JMS. A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials. American Statistician 2021, 75(4), 424-432.
• Abbas R, Wason J, Michiels S, Le Teuff G. A two-stage drop-the-losers design for time-to-event outcome using a historical control arm. Pharmaceutical Statistics 2022, 21(1), 268-288.
• Mukherjee A, Grayling MJ, Wason JMS. Adaptive designs: Benefits and cautions for neurosurgery trials. World Neurosurgery 2022, 161, 316-322.
• Mossop H, Grayling MJ, Gallagher FA, Welsh SJ, Stewart GD, Wason JMS. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials. British Journal of Cancer 2022, 126, 204-210.
• Wilson DT, Wason JMS, Brown J, Farrin AJ, Walwyn REA. Bayesian design and analysis of external pilot trials for complex interventions. Statistics in Medicine 2021, 40(12), 2877-2892.
• Wason JMS, Robertson DS. Controlling type I error rates in multi‐arm clinical trials: A case for the false discovery rate. Pharmaceutical Statistics 2021, 20(1), 109-116.
• Wilson N, Biggs K, Bowden S, Brown J, Dimairo M, Flight L, Hall J, Hockaday A, Jaki T, Lowe R, Murphy C, Pallmann P, Pilling MA, Snowdon C, Sydes MR, Villar SS, Weir CJ, Welburn J, Yap C, Maier R, Hancock H, Wason JMS. Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project. BMC Medicine 2021, 19(1), 251.
• McMenamin M, Barrett JK, Berglind A, Wason JMS. Employing a latent variable framework to improve efficiency in composite endpoint analysis. Statistical Methods in Medical Research 2021, 30(3), 702-716.
• Grayling MJ, Wason JMS, Mander AP. Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables. Communications in Statistics - Theory and Methods 2021, 50(1), 18-34.
• Woitek R, McLean MA, Ursprung S, Rueda OM, Garcia RM, Locke MJ, Beer L, Baxter G, Rundo L, Provenzano E, Kaggie JD, Patterson A, Frary A, Field-Rayner J, Papalouka V, Kane J, Benjamin AJV, Gill AB, Priest AN, Lewis DY, Russell R, Grimmer A, White B, Latimer EC, Patterson I, Schiller A, Carmo B, Slough R, Lanz T, Wason J, Schulte RF, Chin S-F, Graves MJ, Gilbert FJ, Abraham J, Caldas C, Brindle KM, Sala E, Gallagher FA. Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients. Cancer Research 2021, 81(23), 6004-6017.
• Grayling MJ, Bigirumurame T, Cherlin S, Ouma L, Zheng H, Wason JMS. Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential. BMC Rheumatology 2021, 5, 21.
• Vergis N, Phillips R, Cornelius V, Katsarou A, Youngstein T, Cook L, Willicombe M, Pilay C, Shturova T, Almonte M, Charania A, Turner R, Kon OM, Cooke G, Thursz M, Cherlin S, Wason J, Milojkovic D, Innes AJ, Cooper N. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. Trials 2021, 22(1), 270.
• Egle M, Hilal S, Tuladhar AM, Pirpamer L, Hofer E, Duering M, Wason J, Morris RG, Dichgans M, Schmidt R, Tozer DJ, Chen C, de Leeuw F, Markus HS. Prediction of dementia using diffusion tensor MRI measures: the OPTIMAL collaboration. Journal of Neurology, Neurosurgery, and Psychiatry 2022, 93(1), 14-23.
• Collins A, Lendrem D, Wason J, Tarn J, Howard-Tripp N, Bodewes I, Versnel MA, Gottenberg J-E, Seror R, Mariette X, Ng W-F. Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatology International 2021, 41, 1593-1600.
• Lee KM, Brown LC, Jaki T, Stallard N, Wason J. Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials 2021, 22, 203.
• Ouma LO, Grayling MJ, Zheng H, Wason J. Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. Pharmaceutical Statistics 2021, 20(6), 990-1001.
• Wang J, Patel A, Wason JMS, Newcombe PJ. Two-stage penalized regression screening to detect biomarker–treatment interactions in randomized clinical trials. Biometrics 2022, 78(1), 141-150.
• Wason J, Seaman S. A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints. Statistical Methods in Medical Research 2020, 29(1), 230-242.
• Grayling M, Wason J. A web application for the design of multi-arm clinical trials. BMC Cancer 2020, 20, 80.
• Wason J, McMenamin M, Dodd S. Analysis of responder-based endpoints: improving power through utilising continuous components. Trials 2020, 21, 427.
• Zheng H, Wason JMS. Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy. Biostatistics 2022, 23(1), 120-135.
• Witham MD, Wason J, Dodds RM, Sayer AA. Developing a composite outcome measure for frailty prevention trials – rationale, derivation and sample size comparison with other candidate measures. BMC Geriatrics 2020, 20, 113.
• Witham MD, Anderson E, Carroll C, Dark PM, Down K, Hall AS, Knee J, Maier RH, Mountain GA, Nestor G, Oliva L, Prowse SR, Tortice A, Wason J, Rochester L. Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. Trials 2020, 21, 694.
• Cherlin S, Wason JMS. Developing and testing high‐efficacy patient subgroups within a clinical trial using risk scores. Statistics in Medicine 2020, 39(24), 3285-3298.
• Stallard N, Hampson L, Benda N, Brannath W, Burnett T, Friede T, Kimani PK, Koenig F, Krisam J, Mozgunov P, Posch M, Wason J, Wassmer G, Whitehead J, Williamson SF, Zohar S, Jaki T. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research 2020, 12(4), 483-497.
• Lin C, Wason J. Efficient analysis of time-to-event endpoints when the event involves a continuous variable crossing a threshold. Journal of Statistical Planning and Inference 2020, 208, 119-129.
• Witham MD, Anderson E, Carroll C, Dark PM, Down K, Hall AS, Knee J, Maher ER, Maier RH, Mountain GA, Nestor G, O'Brien JT, Oliva L, Wason J, Rochester L. Ensuring that COVID-19 research is inclusive: guidance from the NIHR INCLUDE project. BMJ Open 2020, 11(10), e043634.
• Robertson DS, Wason JMS, Bretz F. Graphical approaches for the control of generalized error rates. Statistics in Medicine 2020, 39(23), 3135-3155.
• Gallagher F, Woitek R, McLean M, Gill A, Garcia R, Provenzano E, Riemer F, Kaggie J, Chhabra A, Ursprung S, Grist J, Daniels C, Zaccagna F, Laurent M, Locke M, Hilborne S, Frary A, Torheim T, Boursnell C, Schiller A, Patterson I, Slough R, Carmo B, Kane J, Biggs H, Harrison E, Deen S, Patterson A, Lanz T, Kingsbury Z, Ross M, Basu B, Baird R, Lomas D, Sala E, Wason J, Rueda O, Chin S, Wilkinson I, Graves M, Abraham J, Gilbert F, Caldas C, Brindle K. Imaging breast cancer using hyperpolarized carbon-13 MRI. Proceedings of the National Academy of Sciences of the United States of America 2020, 117(4), 2092-2098.
• Lee K, Wason J. Including non-concurrent control patients in the analysis of platform trials: is it worth it?. BMC Medical Research Methodology 2020, 20, 165.
• Fonagy P, Yakeley J, Gardner T, Simes E, McMurran M, Moran P, Crawford M, Frater A, Barrett B, Cameron A, Wason J, Pilling S, Butler S, Bateman A. Mentalization for Offending Adult Males (MOAM): study protocol for a randomized controlled trial to evaluate mentalization-based treatment for antisocial personality disorder in male offenders on community probation. Trials 2020, 21, 1001.
• Brown S, Nixon J, Ransom M, Gilberts R, Dewhirst N, McGinnis E, Longo R, Game F, Bojke C, Chadwick P, Chandrasekar A, Chetter I, Collier H, Fernandez C, Homer-Vanniasinkam S, Jude E, Leigh R, Lomas R, Vowden P, Wason J, Sharples L, Russell D. Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): study protocol for a randomised controlled trial. BMJ Open 2020, 10, e035947.
• Fonagy P, Butler S, Cottrell D, Scott S, Pilling S, Eisler I, Fuggle P, Kraam A, Byford S, Wason J, Smith JA, Anokhina A, Ellison R, Simes E, Ganguli P, Allison E, Goodyer IM. Multisystemic therapy compared with management as usual for adolescents at risk of offending: the START II RCT. Health Services and Delivery Research 2020, 8(23).
• Fonagy P, Butler S, Cottrell D, Scott S, Pilling S, Eisler I, Fuggle P, Kraam A, Byford S, Wason J, Smith JA, Anokhina A, Ellison R, Simes E, Ganguli P, Allison E, Goodyer IM. Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): 5-year follow-up of a pragmatic, randomised, controlled, superiority trial. Lancet Psychiatry 2020, 7(5), 420-430.
• Khan MS, Khan MS, Ansari ZN, Siddiqi TJ, Khan SU, Riaz IB, Asad ZA, Mandrola J, Wason J, Warraich HJ, Stone GW, Bhatt DL, Kapadia SR, Kalra A. Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals. JAMA Network Open 2020, 3(4), e203082.
• Al-Olama A, Wason J, Tuladhar A, van Leijsen E, Koini M, Hofer E, Morris R, Schmidt R, de Leeuw F, Markus HS. Simple MRI scores aids prediction of dementia in cerebral small vessel disease. Neurology 2020, 94(12), e1294-e1302.
• Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious S, Mander A, Weir C, Koenig F, Walton M, Nicholl J, Coates E, Biggs K, Hamasaki T, Proschan M, Scott J, Ando Y, Hind D, Altman D. The Adaptive designs CONSORT Extension (ACE) Statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. British Medical Journal 2020, 369, m115.
• Grayling MJ, Mander AP, Wason JMS. Admissible multiarm stepped-wedge cluster randomized trial designs. Statistics in Medicine 2019, 38(7), 1103-1119.
• Dua S, Ruiz-Garcia M, Bond S, Durham SR, Kimber I, Mills C, Roberts G, Skypala I, Wason J, Ewan P, Boyle R, Clark A. Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: A randomized controlled study. Journal of Allergy and Clinical Immunology 2019, 144(6), 1584-1594.e2.
• Robertson D, Wason J. Familywise error control in multi-armed response-adaptive trials. Biometrics 2019, 75(3), 885-894.
• Michiels S, Wason J. Overestimated treatment effects in randomised phase II trials: What's up doctor?. European Journal of Cancer 2019, 123, 116-117.
• Lee K, Wason J, Stallard N. To add or not to add a new treatment arm to a multi-arm study: a decision-theoretic framework. Statistics in Medicine 2019, (ePub ahead of Print).
• Grayling MJ, Mander AP, Wason JMS. Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies. Statistics in Biopharmaceutical Research 2019, 11(4), 360-374.
• Wason J, Brocklehurst P, Yap C. When to keep it simple - adaptive designs are not always useful. BMC Medicine 2019, 17, 152.
• Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JMS, Weir CJ, Wheeler GM, Yap C, Jaki T. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine 2018, 16(1), 29.
• Grayling MJ, Wason JMS, Mander AP. An optimised multi-arm multi-stage clinical trial design for unknown variance. Contemporary Clinical Trials 2018, 67, 116-120.
• Grayling MJ, Mander AP, Wason JMS. Blinded and unblinded sample size re-estimation in crossover trials balanced for period. Biometrical Journal 2018, 60(5), 917-933.
• Grayling MJ, Mander AP, Wason JMS. Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials. Biometrical Journal 2018, 60(5), 903-916.
• Grayling MJ, Wason JMS, Mander AP. Group Sequential Clinical Trial Designs for Normally Distributed Outcome Variables. The Stata Journal 2018, 18(2), 416-431.
• Grayling MJ, Wason JMS, Mander AP. Group sequential crossover trial designs with strong control of the familywise error rate. Sequential Analysis 2018, 37(2), 174-203.
• McMenamin M, Berglind A, Wason JMS. Improving the analysis of composite endpoints in rare disease trials. Orphanet Journal of Rare Diseases 2018, 13, 81.
• Jaki T, Wason JMS. Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study. BMC Cardiovascular Disorders 2018, 18(1), 215.
• Fonagy P, Butler S, Cottrell D, Scott S, Pilling S, Eisler I, Fuggle P, Kraam A, Byford S, Wason J, Ellison R, Simes E, Ganguli P, Allison E, Goodyer I. Multisystemic Therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a randomised controlled pragmatic effectiveness superiority trial. Lancet Psychiatry 2018, 5(2), 119-133.
• Villar SS, Bowden J, Wason J. Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?. Pharmaceutical Statistics 2018, 17(2), 182-197.
• Wason J, Stallard N, Bowden J, Jennison C. A multi-stage drop-the-losers design for multi-arm clinical trials. Statistical Methods in Medical Research 2017, 26(2), 508-524.
• Grayling MJ, Wason JMS, Mander AP. Group sequential designs for stepped-wedge cluster randomised trials. Clinical Trials 2017, 14(5), 507-517.
• O'Connor JPB, Aboagye EO, Adams JE, Aerts HJWL, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, Desouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh D-M, Lacombe D, Lambin P, Lassau N, Leach MO, Lee T-Y, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJM, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, Van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC. Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology 2017, 14(3), 169-186.
• Lin C-J, Wason JMS. Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements. Statistics in Medicine 2017, 36(29), 4616-4626.
• Grayling MJ, Wason JMS, Mander AP. Stepped wedge cluster randomized controlled trial designs: A review of reporting quality and design features. Trials 2017, 18, 33.
• Barrett T, Tanner J, Gill AB, Slough RA, Wason J, Gallagher FA. The longitudinal effect of ejaculation on seminal vesicle fluid volume and whole-prostate ADC as measured on prostate MRI. European Radiology 2017, 27(12), 5236-5243.
• Kunz C, Wason J, Kieser M. Two-stage phase II oncology designs using short-term endpoints for early stopping. Statistical Methods in Medical Research 2017, 26(4), 1671-1683.
• Wason J, Jaki T. A review of statistical designs for improving the efficiency of phase II studies in oncology. Statistical Methods in Medical Research 2016, 25(3), 1010-1021.
• Spencer A, Harbron C, Mander A, Wason J, Peers I. An adaptive design for updating the threshold value of a continuous biomarker. Statistics in Medicine 2016, 35(27), 4909-4923.
• Pandit L, Malli C, Singhal B, Wason J, Malik O, Sawcer S, Ban M, DCunha A, Mustafa S. HLA associations in South Asian multiple sclerosis. Multiple Sclerosis Journal 2016, 22(1), 19-24.
• Ring H, Gilbert N, Hook R, Platt A, Smith C, Irvine F, Donaldson C, Jones E, Kelly J, Mander A, Murphy C, Pennington M, Pullen A, Redley M, Rowe S, Wason J. Improving outcomes in adults with epilepsy and intellectual disability (EpAID) using a nurse-led intervention: study protocol for a cluster randomised controlled trial. Trials 2016, 17, 297.
• Wason J, Jenkins M. Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary method. Rheumatology 2016, 55(10), 1796-1802.
• Wason J, Magirr D, Law M, Jaki T. Some recommendations for multi-arm multi-stage trials. Statistical Methods in Medical Research 2016, 25(2), 716-727.
• Law L, Edirishinghe N, Wason J. Use of an embedded, micro-randomised trial to investigate non-compliance in telehealth interventions. Clinical Trials 2016, 13(4), 417-424.
• Wason J, Abraham J, Baird R, Gournaris J, Vallier A, Brenton J, Earl H, Mander A. A Bayesian adaptive design for biomarker trials with linked treatments. British Journal of Cancer 2015, 113(5), 699-705.
• Fonagy P, Butler S, Baruch G, Byford S, Seto M, Wason J, Wells C, Greisbach J, Ellison R, Simes E. Evaluation of multisystemic therapy pilot services in Services for Teens Engaging in Problem Sexual Behaviour (STEPS-B): study protocol for a randomized controlled trial. Trials 2015, 16, 492.
• Villar SS, Bowden J, Wason J. Multi-armed bandit models for the optimal design of clinical trials: Benefits and challenges. Statistical Science 2015, 30(2), 199-215.
• Nikolic MZ, Lok LSC, Mattishent K, Barth S, Yung B, Cummings NM, Wade D, Vali Y, Chong K, Wilkinson A, Mikolasch T, Brij S, Jenkins HS, Kamath AV, Pasteur M, Hopkins TG, Wason J, Marciniak SJ. Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax. European Respiratory Journal 2015, 45(6), 1731-1734.
• Wason J. OptGS – An R package for finding near-optimal group-sequential designs. Journal of Statistical Software 2015, 66(2).
• Gerety E, Lawrence E, Wason J, Yan H, Hilborne S, Buscombe J, Cheow H, Shaw A, Bird N, Fife K, Heard S, Lomas D, Matakidou A, Soloviev D, Eisen T, Gallagher F. Prospective study evaluating the relative sensitivty of ¹⁸F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and ^99mTc-MDP bone scintigraphy, using an adaptive trial design. Annals of Oncology 2015, 26(10), 2113-2118.
• Villar SS, Wason J, Bowden J. Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule. Biometrics 2015, 71(4), 969-978.
• Wason JMS, Mander AP. The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected. Statistical Methods in Medical Research 2015, 24(6), 909-919.
• Wason JMS, Dentamaro A, Eisen TG. The power of phase II end-points for different possible mechanisms of action of an experimental treatment. European Journal of Cancer 2015, 51(8), 984-992.
• Wason JMS, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Statistics in Medicine 2014, 33(13), 2206-2221.
• Wason J, Marshall A, Dunn J, Stein RC, Stallard N. Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. British Journal of Cancer 2014, 110(8), 1950-1957.
• Fiddes B, Wason J, Sawcer S. Comment on: Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of Clinical and Translational Neurology 2014, 1(5), 375-375.
• Fiddes B, Wason J, Sawcer S. Confounding in association studies: Month of birth and multiple sclerosis. Journal of Neurology 2014, 261(10), 1851-1856.
• Wason JMS, Stecher L, Mander AP. Correcting for multiple-testing in multi-arm trials: Is it necessary and is it done?. Trials 2014, 15, 364.
• Law LM, Wason JMS. Design of telehealth trials - Introducing adaptive approaches. International Journal of Medical Informatics 2014, 83(12), 870-880.
• Wason JMS. Recent developments in group-sequential designs. In: Developments in Statistical Evaluation of Clinical Trials. Berlin: Springer, 2014, pp.97-118.
• Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VAG, Vittori D, Fornasiero A, Chiara Buscarinu M, International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium2, Romano S, Salvetti M, Ristori G. A "Candidate-Interactome" Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis. PLoS ONE 2013, 8(5), e63300.
• Fiddes B, Wason J, Kemppinen A, Ban M, Compston A, Sawcer S. Confounding underlies the apparent month of birth effect in multiple sclerosis. Annals of Neurology 2013, 73(6), 714-720.
• Fonagy P, Butler S, Goodyer I, Cottrell D, Scott S, Pilling S, Eisler I, Fuggle P, Kraam A, Byford S, Wason J, Haley R. Evaluation of multisystemic therapy pilot services in the Systemic Therapy for At Risk Teens (START) trial: Study protocol for a randomised controlled trial. Trials 2013, 14, 265.
• Wason JMS, Jaki T, Stallard N. Planning multi-arm screening studies within the context of a drug development program. Statistics in Medicine 2013, 32(20), 3424-3435.
• Wason JMS. Reducing the average number of patients needed in a phase II trial through novel design. Clinical Research and Regulatory Affairs 2013, 30(4), 47-54.
• Dalton LE, Clarke HJ, Knight J, Lawson MH, Wason J, Lomas DA, Howat WJ, Rintoul RC, Rassl DM, Marciniak SJ. The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. British Journal of Cancer 2013, 108(6), 1340-1347.
• Wason JMS, Seaman SR. Using continuous data on tumour measurements to improve inference in phase II cancer studies. Statistics in Medicine 2013, 32(26), 4639-4650.
• Wason JMS, Dudbridge F. A General framework for two-stage analysis of genome-wide association studies and its application to case-control studies. American Journal of Human Genetics 2012, 90(5), 760-773.
• Mander AP, Wason JMS, Sweeting MJ, Thompson SG. Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis. Pharmaceutical Statistics 2012, 11(2), 91-96.
• Bowden J, Wason J. Identifying combined design and analysis procedures in two-stage trials with a binary end point. Statistics in Medicine 2012, 31(29), 3874-3884.
• Wason JMS, Jaki T. Optimal design of multi-arm multi-stage trials. Statistics in Medicine 2012, 31(30), 4269-4279.
• Wason JM, Mander AP, Thompson SG. Optimal multistage designs for randomised clinical trials with continuous outcomes. Statistics in Medicine 2012, 31(4), 301-312.
• Sawcer S, Wason J. Risk in complex genetics: "all models are wrong but some are useful". Annals of Neurology 2012, 72(4), 502-509.
• Wason JMS, Mander AP. Stage phase II clinical trials with continuous outcomes. Journal of Biopharmaceutical Statistics 2012, 22(4), 836-852.
• Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, White J, Wason J, Parashar D, Armstrong G, Mazhar D, Williams MV. Accelerated BEP: A phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. British Journal of Cancer 2011, 105(6), 766-772.
• The International Multiple Sclerosis Genetics Consortium, The Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476, 214-219.
• Wason JMS, Mander AP, Eisen TG. Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points. European Journal of Cancer 2011, 47(7), 983-989.
• Ban M, McCauley JL, Zuvich R, Baker A, Bergamaschi L, Cox M, Kemppinen A, D'Alfonso S, Guerini FR, Lechner-Scott J, Dudbridge F, Wason J, Robertson NP, De Jager PL, Hafler DA, Barcellos LF, Ivinson AJ, Sexton D, Oksenberg JR, Hauser SL, Pericak-Vance MA, Haines J, Compston A, Sawcer S. A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis. Genes and Immunity 2010, 11(8), 660-664.
• Wason JMS, Dudbridge F. Comparison of multimarker logistic regression models, with application to a genomewide scan of schizophrenia. BMC Genetics 2010, 11, 80.
• Sawcer S, Ban M, Wason J, Dudbridge F. What role for genetics in the prediction of multiple sclerosis?. Annals of Neurology 2010, 67(1), 3-10.
• Ban M, Goris A, Lorentzen AR, Baker A, Mihalova T, Ingram G, Booth DR, Heard RN, Stewart GJ, Bogaert E, Dubois B, Harbo HF, Celius EG, Spurkland A, Strange R, Hawkins C, Robertson NP, Dudbridge F, Wason J, De Jager PL, Hafler D, Rioux JD, Ivinson AJ, McCauley JL, Pericak-Vance M, Oksenberg JR, Hauser SL, Sexton D, Haines J, Sawcer S, The Wellcome Trust Case-Control Consortium (WTCCC), Compston A. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. European Journal of Human Genetics 2009, 17(10), 1309-1313.